{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 33/80', '16.', 'Criterion modified per amendment.', '16.1. Taking medication known to be potent inducers of P-gp (Appendix 2) within 4', 'weeks or 5 half-lives of the drug (whatever is longer) prior to the baseline visit.', '17.', 'Criterion modified per amendment.', '17.1. Taking medication known to be potent inhibitors of P-gp (Appendix 4) within', '4 weeks or 5 half-lives of the drug (whatever is longer) prior to the baseline', 'visit.', '18.', 'Abnormal liver function test (LFT) at screening, defined as aspartate aminotransferase', '(AST), and/or alanine aminotransferase (ALT), and/or bilirubin, and/or alkaline', 'phosphatase >2x upper limit of normal (ULN). Retesting is allowed once.', '19.', 'Criterion modified per amendment.', '19.1. Abnormal renal function at screening, defined as estimated glomerular', 'filtration rate (eGFR) <60 mL/min/1.73 m\u00b2 using the Chronic Kidney Disease', 'Epidemiology Collaboration (CKD-EPI) equation. Retesting is allowed once.', '20.', 'Hemoglobin level <10 g/dL at screening. Retesting is allowed once.', '21.', 'Concurrent participation or participation in a drug, drug/device, or biologic', 'investigational research study within 5 half-lives of the IMP (or within 8 weeks when', 'half-life is unknown) prior to the baseline visit, or prior participation in an', 'investigational antibody study within 6 months prior to the baseline visit.', '22.', 'Gastrointestinal involvement (e.g. unable to swallow) preventing oral administration', 'of IMP.', '23.', 'Subjects diagnosed with:', 'Systemic sclerosis sine scleroderma, or', 'Localized scleroderma, or', 'Eosinophilic fasciitis, eosinophilia myalgia syndrome.', '24.', 'Diagnosis of another connective tissue disorder by ACR criteria.', '25.', 'History of diverticulosis requiring antibiotic treatment or any other gastrointestinal', 'condition that might predispose to perforations.', '26.', 'Investigator or other study staff or relative thereof who is directly involved in the', 'conduct of the study.', '27.', 'Significant blood loss (including blood donation [>450 mL]), or transfusion of any', 'blood product within 12 weeks prior to the baseline visit.', '28.', 'Active drug or alcohol abuse (more than 3 glasses of wine or beer or equivalent/day)', 'within 2 years prior to first IMP intake.', '29.', 'Any other clinical condition or circumstances that in the opinion of the investigator', 'may make a subject unsuitable for inclusion or unable to complete the study or comply', 'with study procedures and requirements.', '30.', 'A history of being admitted to an institution under an administrative or court order, if', 'applicable by local legislation.', '4.5.3. Prohibition and Restrictions', '4.5.3.1.', 'Precautions for Sexual Intercourse', 'Highly effective contraceptive measures for both males and females of childbearing potential', 'must be documented in the source documents.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 34/80', '4.5.3.1.1.', 'Female subjects', \"In line with the Heads of Medicines Agencies (HMA)'s Clinical Trial Facilitation Group\", '(CTFG) recommendation, female subjects are considered of non-childbearing potential if they', 'meet one of the following criteria:', '- No menses for 12 or more months without an alternative medical cause. A high follicle', 'stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a', 'postmenopausal state in women not using hormonal contraception or hormonal', 'replacement therapy. However in the absence of 12 months of amenorrhea, a single', 'FSH measurement is insufficient.', '-', 'Permanently surgically sterile (bilateral oophorectomy [i.e. surgical removal of ovaries],', 'bilateral salpingectomy, or hysterectomy [i.e. surgical removal of uterus]).', 'All other female subjects are considered to be of childbearing potential (WOCBP) and must', 'use one of the following highly effective methods of birth control prior to the first dose of', 'IMP, during the clinical study and for at least 30 days after the last dose of IMP:', '-', 'Combined (estrogen and progesterone containing) (oral, intravaginal, transdermal)', 'hormonal contraception associated with inhibition of ovulation plus a barrier method1.', '-', 'Progesterone-only hormonal (oral, injectable, implantable) contraception associated', 'with inhibition of ovulation plus a barrier method1.', '-', 'Intrauterine device.', '-', 'Intrauterine hormone-releasing system.', '-', 'Bilateral tubal occlusion.', '-', 'Sexual abstinence defined as refraining from heterosexual intercourse during the entire', 'period of risk associated with the study treatments. The reliability of sexual abstinence', 'needs to be evaluated in relation to the duration of the clinical study and the preferred', 'and usual lifestyle of the subject.', 'Periodic abstinence (e.g. calendar, symptothermal, post-ovulation methods), declaration of', 'abstinence for the duration of a clinical study, withdrawal, spermicides only, and lactational', 'amenorrhea method are not acceptable as methods of contraception.', 'In case a WOCBP has a vasectomized partner, provided that partner is the sole sexual partner', 'of the WOCBP clinical study participant and that the vasectomized partner has received', 'medical assessment of the surgical success, then she is not required to use an additional form', 'of contraception.', 'Within these limits, the specific forms of contraception employed are left to the discretion of', \"the subject, the investigator, and/or the subject's physician.\", 'WOCBP will be requested to do a monthly urine pregnancy test during the treatment period,', 'and a urine pregnancy test at the Follow-up Visit 1. The monthly pregnancy test for Weeks 12', 'and 20 will be performed at home by the subject using home testing kits. The site will', 'construct the subjects on how to use and read the pregnancy tests. The outcome must be', 'documented on the subject diary card and the site will obtain the results during the phone call', 'and record in the source and case report form (CRF). In case of a positive urine pregnancy test', 'at home, the subject should immediately contact the clinical study center and the investigator', '1 As there is no current data available regarding potential interactions between IMP and hormonal contraceptives,', 'female subjects who use hormonal contraception should supplement this with a barrier method (preferably male', 'condom).', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}